Lily Zheng

Lily Zheng

Auto-generated profile, based on publicly available information

Lily Zheng

Institute for Computational Medicine, Johns Hopkins University, Baltimore, Maryland

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2017 in Cell
Verified
Journal Article
Closed access
KYKi-Jun Yoon
Ki-Jun Yoon
FRFrancisca Rojas Ringeling
Francisca Rojas Ringeling
CVCaroline Vissers
Caroline Vissers
FJFadi Jacob
Fadi Jacob
MPMichael Pokrass
Michael Pokrass
HSHongjun Song
Hongjun Song

1 March 2020 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
XSXiaoshan M. Shao
Xiaoshan M. Shao
RBRohit Bhattacharya
Rohit Bhattacharya
JHJustin Huang
Justin Huang
ISI.K. Ashok Sivakumar
I.K. Ashok Sivakumar
CTCollin Tokheim
Collin Tokheim
RKRachel Karchin
Rachel Karchin
Computational prediction of binding between neoantigen peptides and major histocompatibility complex (MHC) proteins can be used to predict patient response to cancer immunotherapy. Current neoantigen predictors focus on in silico estimation of MHC binding affinity and are limited by low predictive value for actual peptide presentation, inadequate support for rare MHC alleles, and poor scalability to high-throughput data sets. To address these limitations, we developed MHCnuggets, a deep neural network method that predicts peptide–MHC binding. MHCnuggets can predict binding for common or rare alleles of MHC class I or II with a single neural network architecture. Using a long short-term memory network (LSTM), MHCnuggets accepts peptides of variable length and is faster than other methods. When compared with methods that integrate binding affinity and MHC-bound peptide (HLAp) data from mass spectrometry, MHCnuggets yields a 4-fold increase in positive predictive value on independent HLAp data. We applied MHCnuggets to 26 cancer types in The Cancer Genome Atlas, processing 26.3 million allele–peptide comparisons in under 2.3 hours, yielding 101,326 unique predicted immunogenic missense mutations (IMM). Predicted IMM hotspots occurred in 38 genes, including 24 driver genes. Predicted IMM load was significantly associated with increased immune cell infiltration (P < 2 × 10−16), including CD8+ T cells. Only 0.16% of predicted IMMs were observed in more than 2 patients, with 61.7% of these derived from driver mutations. Thus, we describe a method for neoantigen prediction and its performance characteristics and demonstrate its utility in data sets representing multiple human cancers.

1 September 2017 in Cell Stem Cell
Verified
Journal Article
Closed access
KYKi-Jun Yoon
Ki-Jun Yoon
GSGuang Song
Guang Song
XQXuyu Qian
Xuyu Qian
JPJianbo Pan
Jianbo Pan
DXDan Xu
Dan Xu
GMGuo-li Ming
Guo-li Ming

1 May 2024 in Nature
Verified
Journal Article
Closed access
PDF file
ABAlicia M. Braxton
Alicia M. Braxton
AKAshley L. Kiemen
Ashley L. Kiemen
MGMia P. Grahn
Mia P. Grahn
AFAndré Forjaz
André Forjaz
JPJeeun Parksong
Jeeun Parksong
LWLaura D. Wood
Laura D. Wood

1 November 2020 in JCO Clinical Cancer Informatics
Verified
Journal Article
Open access
KPKymberleigh A. Pagel
Kymberleigh A. Pagel
RKRick Kim
Rick Kim
KMKyle Moad
Kyle Moad
BBBen Busby
Ben Busby
LZLily Zheng
Lily Zheng
RKRachel Karchin
Rachel Karchin
PURPOSE: The modern researcher is confronted with hundreds of published methods to interpret genetic variants. There are databases of genes and variants, phenotype-genotype relationships, algorithms that score and rank genes, and in silico variant effect prediction tools. Because variant prioritization is a multifactorial problem, a welcome development in the field has been the emergence of decision support frameworks, which make it easier to integrate multiple resources in an interactive environment. Current decision support frameworks are typically limited by closed proprietary architectures, access to a restricted set of tools, lack of customizability, Web dependencies that expose protected data, or limited scalability. METHODS: We present the Open Custom Ranked Analysis of Variants Toolkit 1 (OpenCRAVAT) a new open-source, scalable decision support system for variant and gene prioritization. We have designed the resource catalog to be open and modular to maximize community and developer involvement, and as a result, the catalog is being actively developed and growing every month. Resources made available via the store are well suited for analysis of cancer, as well as Mendelian and complex diseases. RESULTS: OpenCRAVAT offers both command-line utility and dynamic graphical user interface, allowing users to install with a single command, easily download tools from an extensive resource catalog, create customized pipelines, and explore results in a richly detailed viewing environment. We present several case studies to illustrate the design of custom workflows to prioritize genes and variants. CONCLUSION: OpenCRAVAT is distinguished from similar tools by its capabilities to access and integrate an unprecedented amount of diverse data resources and computational prediction methods, which span germline, somatic, common, rare, coding, and noncoding variants.

1 October 2019 in Gastroenterology
Verified
Journal Article
Open access
PDF file
CFCatherine G. Fischer
Catherine G. Fischer
VGVioleta Beleva Guthrie
Violeta Beleva Guthrie
ABAlicia M. Braxton
Alicia M. Braxton
LZLily Zheng
Lily Zheng
PWPei Wang
Pei Wang
LWLaura D. Wood
Laura D. Wood
Background & Aims Intraductal papillary mucinous neoplasms (IPMNs) are lesions that can progress to invasive pancreatic cancer and constitute an important system for studies of pancreatic tumorigenesis. We performed comprehensive genomic analyses of entire IPMNs to determine the diversity of somatic mutations in genes that promote tumorigenesis. Methods We microdissected neoplastic tissues from 6–24 regions each of 20 resected IPMNs, resulting in 227 neoplastic samples that were analyzed by capture-based targeted sequencing. Somatic mutations in genes associated with pancreatic tumorigenesis were assessed across entire IPMN lesions, and the resulting data were supported by evolutionary modeling, whole-exome sequencing, and in situ detection of mutations. Results We found a high prevalence of heterogeneity among mutations in IPMNs. Heterogeneity in mutations in KRAS and GNAS was significantly more prevalent in IPMNs with low-grade dysplasia than in IPMNs with high-grade dysplasia (P < .02). Whole-exome sequencing confirmed that IPMNs contained multiple independent clones, each with distinct mutations, as originally indicated by targeted sequencing and evolutionary modeling. We also found evidence for convergent evolution of mutations in RNF43 and TP53, which are acquired during later stages of tumorigenesis. Conclusions In an analysis of the heterogeneity of mutations throughout IPMNs, we found that early-stage IPMNs contain multiple independent clones, each with distinct mutations, indicating their polyclonal origin. These findings challenge the model in which pancreatic neoplasms arise from a single clone. Increasing our understanding of the mechanisms of IPMN polyclonality could lead to strategies to identify patients at increased risk for pancreatic cancer.